Abstract
Using primary human intestinal epithelial cells and brain microvascular endothelial cells （BMECs） for the evaluation of drug membrane permeability would be desirable, but they have poor viability and other characteristics such as short life span that limit their application. In addition, it is very difficult to obtain primary human small intestinal epithelial cells and BMECs for drug discovery research such as pharmacokinetic studies and safety tests of drug candidates. To accurately predict the pharmacokinetics of the human small intestine and blood–brain barrier （BBB）, the development of human induced pluripotent stem （iPS） cell–derived intestinal epithelial cells and brain microvascular endothelial-like cells has been needed, which would have functions similar to normal human intestinal epithelial cells and BMECs. In this review, we describe the development research of small intestinal epithelial cells, intestinal organoids and BMECs differentiated from human iPS cells to construct of drug discovery research support models.
